In 2020, the global Intravenous (IV) Ibuprofen Market was valued at $5.34 million. Projections indicate that this market will reach $15.48 million by 2030, registering a CAGR of 13.4% from 2021 to 2030. This robust growth is attributed to factors such as the rising incidence of conditions like arthritis, cardiovascular diseases, and various cancers, which necessitate effective pain management strategies. The global Intravenous (IV) Ibuprofen Market has witnessed significant growth in recent years, driven by the increasing prevalence of chronic diseases, advancements in healthcare infrastructure, and a rising demand for effective pain management solutions. As a non-steroidal anti-inflammatory drug (NSAID), intravenous ibuprofen offers rapid analgesic and anti-inflammatory effects, making it a preferred choice in various clinical settings.
Get Sample PDF Copy: https://www.alliedmarketresearch.com/request-sample/1387
Intravenous (IV) Ibuprofen Market Growth Factors
- Prevalence of Chronic Diseases: The increasing occurrence of diseases such as osteosarcoma, nerve cancer, and leukemia has led to a heightened demand for effective pain management solutions. For instance, in 2021, approximately 3,910 new cases of bone cancers were diagnosed in the U.S.
- Advancements in Healthcare Infrastructure: The expansion of orthopedic hospitals and diagnostic centers has facilitated better diagnosis and treatment of musculoskeletal disorders. In 2020, the U.S. had over 30,500 orthopedic surgeons, underscoring the extensive infrastructure supporting orthopedic care.
- High Bioavailability and Rapid Action: Intravenous ibuprofen is favored for its high bioavailability and swift analgesic effects, making it suitable for managing mild to severe pain in both pediatric and adult patients.
- Regulatory Approvals and Product Availability: The approval of intravenous ibuprofen formulations by regulatory bodies, such as the U.S. Food and Drug Administration (FDA), has expanded its therapeutic applications. Additionally, the availability of over-the-counter ibuprofen enhances its accessibility for pain management.
Intravenous (IV) Ibuprofen Market Segmentation
The Intravenous (IV) Ibuprofen Market is segmented based on indication, age group, and region.
- By Indication:
- Pain/Inflammatory: This segment dominates the market due to the widespread use of IV ibuprofen in managing conditions like musculoskeletal disorders and postoperative pain.
- Fever: IV ibuprofen is also employed in reducing fever, particularly when oral administration is not feasible.
- By Age Group:
- Adults: Comprising the largest share, the adult segment benefits from the high prevalence of chronic pain conditions and the extensive use of IV ibuprofen in surgical settings.
- Pediatrics: This segment is expected to witness significant growth, driven by the increasing pediatric population and the FDA’s approval of IV ibuprofen for use in children.
- By Region:
- United States: Leading the market with nearly half of the global share in 2020, the U.S. market is propelled by a high incidence of bone cancer and a well-established healthcare infrastructure.
- China: Anticipated to register the fastest growth with a CAGR of 15.25% by 2030, driven by an increasing number of hospitals, a high pediatric population, and a rising prevalence of cancer.
Have Any Query? Ask Our Experts: https://www.alliedmarketresearch.com/purchase-enquiry/1387
Key Players in the Intravenous (IV) Ibuprofen Market
The Intravenous (IV) Ibuprofen Market features several prominent players contributing to its growth:
- AFT Pharmaceuticals
- Cumberland Pharmaceuticals Inc.
- Dano Health Group
- Grifol
- Harbin Gloria Pharmaceuticals Co., Ltd.
- Hyloris Pharmaceuticals SA
- Pharma Bavaria International
- Recordati
- SG Pharma
- XGEN
These companies are actively engaged in research and development, strategic collaborations, and product launches to enhance their market presence and address the growing demand for effective intravenous pain management solutions.
The Intravenous (IV) Ibuprofen Market is poised for substantial growth in the coming years, driven by the increasing prevalence of chronic diseases, advancements in healthcare infrastructure, and a rising demand for rapid and effective pain management therapies. As key players continue to innovate and expand their product offerings, the market is expected to witness enhanced accessibility and adoption of intravenous ibuprofen across various clinical settings.
Procure Complete Report: https://www.alliedmarketresearch.com/intravenous-ibuprofen-market/purchase-options
Thanks for reading this article; you can also get an individual chapter-wise sections or region-wise report versions like North America, LATAM, Europe, or Southeast Asia.
About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Contact Us:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
[email protected]
